Content Type: Article

  • View From McDermott: Fifth Circuit Focuses on Process in ESOP Valuations

    ARTICLE

    View From McDermott: Fifth Circuit Focuses on Process in ESOP Valuations

    June 28, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Allison Wilkerson and Emily Rickard wrote this bylined article on the Fifth Circuit’s Perez v. Bruister decision, which stressed the importance of “process” in valuation determinations used for acquisitions of a corporation’s stock by an employee stock ownership plan (ESOP). ESOPs “are still grappling with valuation issues” which are “an inexact science that involves an inherent level of uncertainty,” the authors wrote, and they analyzed Bruister’s guidance to fiduciaries who review valuations for ESOP transactions.

    In depth
    Authors

    Allison Wilkerson

    Partner

    Dallas

    More insights

  • Brexit Update: What’s Next for the Global Marketplace

    Brexit Update: What’s Next for the Global Marketplace

    ARTICLE / CLIENT ALERT

    Brexit Update: What’s Next for the Global Marketplace

    June 28, 2016

    Read time: 20 min

    Key takeaways
    Overview

    The United Kingdom’s vote to leave the European Union is expected to have complex legal implications for the United Kingdom, the European Union and the global marketplace in the near and long term. McDermott has an experienced team of lawyers who have been evaluating the potential legal ramifications of the June 23 referendum and are ready to answer questions and assist clients in navigating the consequences of the United Kingdom’s exit.

    In depth

    UK Withdrawal Process

    The United Kingdom will continue to be an EU member until procedures are completed for exiting the European Union, which is likely to be a long process. Under EU Treaty rules, the process will begin when the United Kingdom gives notice to the European Union of its intention to leave. It seems unlikely that the UK Government will give notice until a new Prime Minister is in place, which will be in September 2016 at the earliest.

    Any notice will trigger a two year deadline for the United Kingdom and the European Union to negotiate a withdrawal agreement, although the deadline can be extended with the unanimous consent of the remaining EU Member States. During the negotiation period, EU laws and treaties will still apply to the United Kingdom; which means that all laws currently in place will remain in place for at least two years. The final withdrawal agreement will clarify which EU laws and regulations will no longer apply, and which will continue to apply.

    The withdrawal agreement will need to be ratified by the United Kingdom and the European Union before it takes effect, which is likely to take some time. If the two sides cannot come to an agreement on withdrawal after two years, EU treaties, laws and regulations will cease to apply to the United Kingdom, unless the EU Member States unanimously decide to extend the negotiation period.

    The approach that the UK Government will take in negotiations with the EU is unlikely to become clear for some weeks. Some prominent figures have suggested that its key priority will be ensuring that the UK remains within the European single market, to ensure that it continues to benefit from rules guaranteeing the freedom of movement of goods, services, people and capital between participating countries.

    Until the Government has decided on a negotiating position (which may necessitate a General Election first), it seems unlikely that notice will be served under the EU Treaty. The EU has indicated that it is not prepared to enter into informal negotiations over the terms of a Brexit until notice has been served. It is entirely conceivable that the United Kingdom may not serve notice for some time to come.

    Key Legal Implications

    The impact of Brexit will depend on what approach the United Kingdom decides to pursue in its negotiations with the European Union, but the following are some of the most prominent issues for businesses to consider now.

    Trade
    Until the United Kingdom formally exits the European Union, all EU access rules and procedures will continue to apply to all intra-EU trade, including with the United Kingdom, and to imports entering UK ports from third countries.

    Once the United Kingdom gives notice of its intention to leave, however, it will need to renegotiate a new trade relationship with the remainder of the European Union to take effect at the end of the two year period during which the existing treaties still apply. One option could be membership in the European Economic Area (EEA), an arrangement that grants Norway and certain other countries free access to the EU internal market, but doesn’t give them any vote in EU decision-making bodies. Another could be a bilaterally-negotiated agreement with the European Union similar to the arrangement Switzerland has.

    The United Kingdom will also need to renegotiate on its own behalf the free trade agreements (FTAs) and other trade agreements the European Union currently has with dozens of countries around the world, and will likely also pursue trade agreements with the United States, Japan and other countries that are currently negotiating trade deals with the European Union. The United Kingdom may also have to renegotiate its World Trade Organisation (WTO) market-access commitments with WTO member countries.

    To the extent that the European Union loses one of its largest members, it may also be required under trade rules to renegotiate certain of its WTO, regional and bilateral trade commitments. With the European Union’s attentions now primarily directed to managing Brexit fallout, the pace of its FTA trade negotiations with other countries (the United States, Japan, Mercosur and Mexico) may be affected.

    Tax
    One of the most significant potential implications relating to tax is that UK companies may lose access to the EU Parent-Subsidiary or Interest and Royalties directives, which eliminate withholding tax on payment flows between related entities, and may instead have to rely on double tax treaties, not all of which offer a complete withholding tax exemption.

    It seems unlikely that the United Kingdom will be bound by the new anti-tax abuse directive that is scheduled to come into effect from January 1, 2019 and which has largely been inspired by the Organisation for Economic Co-operation and Development Base Erosion and Profit Shifting (BEPS) initiative. It is worth bearing in mind, however, that the United Kingdom is likely to remain committed to introducing BEPS reforms in any event.

    VAT is likely to remain largely unchanged, although the UK Government may have greater freedom to vary the scope and rates of VAT once it is no longer constrained by the EU VAT Directive.

    If the United Kingdom ultimately leaves the EU single market (which guarantees freedom of movement of goods, services, people and capital between member states), it could result in the imposition of customs duties on exports and imports to and from EU countries, with associated compliance costs.

    Competition and State Aid
    At present, the European Commission enforces EU competition law, and the UK regulator—the Competition and Markets Authority (CMA)—enforces both EU and UK competition law. Although both the CMA and the European Commission can enforce EU-wide competition rules, they do not engage in parallel enforcement of the same case. For instance, if a transaction fulfils the thresholds for notification to the European Commission, it will not need to be notified to the CMA, even if the UK thresholds for mergers are met. Likewise, if the European Commission investigates an alleged infringement of EU competition law, the CMA would not undertake the same investigation. This arrangement essentially provides a “one stop shop” merger review process.

    There are many unknown variables at this stage, but it appears that Brexit could lead to increased competition law scrutiny, penalties and uncertainty for businesses. For instance, post-Brexit, merging companies may be obliged to notify the same transaction to both the CMA and the European Commission, no longer benefiting from the European Commission’s one stop shop merger review. Similarly, the CMA and European Commission could investigate the same antitrust infringements, leading to multiple fines for the same conduct.

    EU State aid law applies across the European Union, enforced by the European Commission. In the absence of EU State aid law, the United Kingdom would, in principle, be subject only to WTO rules, but this scenario assumes no trade arrangement between the United Kingdom and the European Union, which is highly unlikely. Alternative scenarios could involve the application of EU State aid law subject to an EU-UK trade agreement, or the promulgation of a UK State aid law.

    Mergers & Acquisitions
    Although transaction volumes may suffer in the short term, and some transactions in the UK market may now be put on hold or simply not take place, the effect of the United Kingdom withdrawing from the European Union will have a marginal effect on the legal principles and practice of M&A transactions under English law.

    In UK public M&A, transactions involving UK public companies will continue to be regulated by the UK Takeover Panel through the City Code on Takeovers and Mergers. While many of its provisions are incorporated into (rather than derive from) the EU Takeover Directive, the Code would not be affected by EU withdrawal, as it is a standalone set of rules subject to resolution ultimately at the Panel level.

    As far as private company M&A is concerned, little if any EU law overrides principles of English contract law and parties are likely to continue to use English law as the basis for commercial transactions—even where there is no UK nexus—owing to the English courts’ long history of commercial case law precedent, tried and tested contractual terms for use in documentation, the impartiality and consistency of the English courts in resolving disputes, and the large body of professionals in London and elsewhere competent to execute transactions effectively under English law.

    There are a few areas where EU law does impact on M&A transactions, such as the Acquired Rights Directive, which is incorporated into UK employment law and acts to automatically transfer employment contracts to a buyer on completion of a business or asset transaction, but this is unlikely to be repealed by the UK Government in the short term.

    The competition implications of Brexit are dealt with above, but the effect of EU withdrawal may act to prolong competition clearance where there is a UK component in a transaction, as the UK component would no longer be aggregated within the EU market calculation and would instead be assessed separately by the domestic UK competition authority.

    Intellectual Property
    Brexit is unlikely to have an impact on European Patents, neither with regard to existing patents and applications, nor with regard to future applications. This is because, despite the name, European Patents are unrelated to the European Union and are therefore not directly affected by Brexit.

    The situation is different with regard to the new European Unitary Patent scheme, which was expected to come into force in early 2017. The United Kingdom will now most likely not be able to join the Unitary Patent system. As a non-EU Member State, the United Kingdom is also unlikely to be able to host a branch of the European Patent Court as previously planned It is extremely likely that the Unitary Patent system will now be renegotiated altogether and that its entry into force will be delayed, for at least one year.

    The destiny of EU trade marks and designs is less clear than that of European Patents as these are linked to the European Union. One possible scenario is that the UK element of such rights will be split off, with a grace period within which the United Kingdom portions of Community IP rights may be converted into national UK rights.

    Health, Pharmaceuticals and Life Sciences
    The European health service sector in Europe will likely not be affected as health services are one of the few industries that are fundamentally not harmonised on a European level at all. As a result, market entry barriers for foreign investors vary considerably among European countries.

    The United Kingdom traditionally has a long history of one predominant public payer (the National Health Service (NHS)) and plans to privatise elements of the NHS in the early years of the Cameron government were largely abandoned due to severe political resistance. In view of the current political turmoil in the United Kingdom following the Brexit vote, it appears very unlikely that a new government, once appointed, will focus on opening the UK health care market to foreign investors.

    The health services of EU Member States will be entirely unaffected by political issues within the United Kingdom.

    The potential for change in the pharmaceutical sector is higher, given that the pharma industry is, to a large extent, harmonised on a European level. The current UK pharmaceutical legislation— from the development of a medicinal product to its approval and post-approval monitoring—derives mostly from European legislation. Only pricing and reimbursement depend on national laws, as European attempts to harmonise them have been limited.

    If the United Kingdom becomes part of the EEA alongside Iceland, Liechtenstein and Norway, most of the EU pharmaceutical legislation will remain relevant, e.g., a marketing authorisation for a medicinal product approved by the European Commission is also valid in the EEA countries. If the United Kingdom adopts the Swiss approach and negotiates multiple bilateral trade deals, with no automatic recognition of EU legislation, the situation will be more complicated.

    What appears very likely, is that the harmonisation of the European pharmaceutical market would not directly apply to the United Kingdom any further. Consequently, the European authority in charge of granting EU market authorisations, the European Medicines Agency (EMA), which is based in London, will have to relocate to an EU Member State. Italy, Sweden and Denmark have already indicated their interest in hosting the EMA.

    Wherever the EMA relocates, it is very likely that foreign, in particular US, pharmaceutical companies that still have their European headquarters in the United Kingdom will relocate those headquarters to the new location.

    Private Client
    Announced in outline only, further details of the proposed changes were expected to follow after the Referendum, with a consultation anticipated in autumn 2016 and the intention of the law coming into force from April 6, 2017. It seems unlikely that these reforms will be a priority of either the present or successor government. If the changes are not enacted as previously expected, the taxation of “non-doms” will continue as before.

    Individuals currently resident in the United Kingdom who were formerly resident in certain other EU jurisdictions, and who are subject to a deferred payment of exit tax liabilities in relation to their prior residence, may find that Brexit triggers payment of the deferred liability by virtue of the individual ceasing to be resident in the European Union. We expect this would occur on the earlier of the date of entry into force of the withdrawal agreement (under Article 50(3)) or on expiry of the two-year notice period (if no withdrawal agreement is in place).

    Finally, individuals resident in the United Kingdom who own assets in an EU country may eventually be subject to a less favourable tax treatment than they currently enjoy.

    Private Equity
    The European operations of many international private equity (PE) sponsors are based in London and authorised by the Financial Conduct Authority. The Alternative Investment Fund Managers’ Directive (AIFMD) currently allows these PE sponsors to market funds to investors across the European Union via a “passport” regime, which will continue to apply for the two year negotiation period.

    If the United Kingdom joins the EEA, access to the single market would be maintained and the impact on financial regulation, including AIFMD, likely to be relatively minimal. A full exit would theoretically result in UK-headquartered PE sponsors losing their passport right to market to investors across the European Union, which could prompt some to set up parallel operations in EU Member States. It is, however, anticipated that the passport regime will be extended to non-EEA PE sponsors by 2018 so, in practice, this extension may address and allay concerns.

    Access to the EU markets by third country investment firms is currently governed by the Markets in Financial Instruments Directive and the Markets in Financial Instruments Regulation (MiFIR), together known as MiFID II, which essentially, grants access to countries that have “equivalent” standards of regulation. One issue to consider is that the MiFIR provisions relate only to segments of the businesses that currently benefit from passporting rights. For example, asset managers that have Undertakings for Collective Investment in Transferable Securities funds domiciled in the United Kingdom for distribution throughout the European Union are not covered. In theory, the United Kingdom should be able to take advantage of the MiFIR provisions because the country meets the guideline for equivalent standards of regulation. That could change, however, if, for example, the United Kingdom revokes the part of the EU bank capital rules that cap bankers’ bonuses, in which case the EU Commission, which must decide on MiFIR eligibility, could turn down the application.

    An alternative, which is currently used by non-EU firms, and which could also be used by UK firms before the passport regime is extended, would be to take advantage of the national private placement regimes of each country where they want to do business. The national private placement regimes allow non-EEA PE sponsors to market and carry out regulated activities on a country-by-country basis. This is a temporary, short term solution if the need arises.

    In respect of transactional matters, as well as the considerations highlighted in the M&A section above, the ability of PE sponsors to conclude UK and EU deals will be dependent on the response of banks and financial institutions both in the United Kingdom and elsewhere to Brexit, and their appetite to lend in the short term.

    In general, PE sponsors and management teams should review the terms of their existing financing arrangements and consider short/medium term liquidity options. Although, based on standard Loan Market Association (LMA) provisions, Brexit is unlikely to constitute an event of default under material adverse changes or force majeure clauses, bespoke arrangements and financial covenants should be reviewed carefully. In the case of the latter, the impact of a devaluation of sterling should be considered in the context of exchange rates to be applied for foreign borrowings. This is of particular importance to those companies due to test covenants on June 30.

    Litigation
    The market volatility arising from Brexit will undoubtedly generate a number of contractual disputes. One key area that will be affected is the relevant jurisdiction of disputes. Currently, the jurisdiction of EU Member States is largely governed by Regulation No 1215/2012 of December 12, 2012, which governs all main civil and commercial matters, apart from certain, well-defined matters, including maintenance. It is likely that the United Kingdom will eventually withdraw from these provisions and return to a conventional common law approach, subject to bilateral and multi-state agreements.

    This could, however, only occur once the two year negotiation period is completed, or a withdrawal agreement is reached, whichever comes earlier. In the meantime, businesses should revisit any jurisdictional advice they have received on disputes involving EU Member States and the United Kingdom to ensure that this will not be adversely affected by a return of a conventional common law approach and/or bilateral and multi-state agreements.

    Energy
    We have been here before; the trading and downstream world has faced seismic shifts over the last 20 years comparable to working through the implications of Brexit. We can draw upon experience of events such as Enron’s demise and the 2008 financial crash. These events had significant knock-on effects and unintended consequences, from which the industry learnt and emerged.

    As far as immediate and forward-looking issues are concerned, careful consideration will have to be given as to whether or not to reopen provisions in ongoing agreements, particularly in the trading and projects space. The circumstances may be remote, but counterparties may need to consider the scope of material adverse change clauses and, potentially, force majeure provisions.

    Going forward, careful attention will, as ever, have to be given to clauses anticipating future changes such as identifying the circumstances that will trigger them, the correct test for the relevant change, the mechanism to settle any differences, and the consequences of any failure to agree or fulfil contracts.

    From the perspective of investment in the United Kingdom, energy policies and laws are driven by many factors, both national and international. The European Union was one dimension of the United Kingdom’s energy sector, but numerous other drivers remain in place. Security of supply, geology, skills within the workforce, local investment priorities and worldwide climate change considerations will all remain in the policy mix going forward.

    It could be argued that the United Kingdom could benefit from potentially greater control over its energy generation mix. While there will be obvious questions raised as to the long term investment profile of projects such as Hinckley Point nuclear power station by companies like EDF, the future for carbon capture and storage and coal fired output may be revisited.

    As far as the outlook for renewables is concerned, from an investment perspective, comfort can be taken from the United Kingdom’s long standing support of these technologies, which is enshrined within the original Electricity Act 1989 on privatisation. Many of the non-political drivers also remain in place.

    In the commodities world, an already complex and evolving picture has simply become more so. Unravelling the financial services regulatory impact will require additional thought by an industry which has already been facing changes for the last eight years.

    Finance
    Existing EU-based legislation underpins much of the cross-border and domestic activity of banks and financial institutions based in the United Kingdom, including through the EU passporting regime. It also facilitates the activities of non-EU-based banks and financial institutions that access EU markets using the United Kingdom as a base, relying on the equivalence process.

    Parties that have transacted under agreements that are governed by English law, or which are subject to the jurisdiction of the English courts, will be considering the immediate and longer term impacts of Brexit, as will parties to agreements entered into by non-UK parties (whether in the European Union or elsewhere) with parties located in the United Kingdom, and vice versa, whether they are banks or financial institutions (or UK branches of the same), borrowers or guarantors.

    In the immediate term, in the vast majority of instances there should not be any immediate impact on such agreements. On June 24, 2016 the Loan Market Association (LMA) issued a statement to this effect in relation to LMA based agreements. All applicable contractual and legislative regimes continue for now. Except in transaction- or party-specific scenarios, it is unlikely that default provisions, e.g., material adverse effect clauses, will have been triggered by the Referendum or the subsequent market turmoil. Parties should, however, give some consideration to their position under their relevant existing contracts.

    As the Brexit process moves forward and the shape of the post-Brexit regime becomes clearer, additional detailed due diligence will be required. In due course some amendments may be required to existing agreements.

    Currently these are anticipated to be relatively minor, but this will depend on what Brexit arrangements are agreed (or not agreed). Parties currently negotiating relevant agreements will also need to consider the Brexit process.

    Employment
    A significant proportion of UK employment laws derive from the European Union. Those laws will continue to apply unchanged during the two year period of negotiation. Notably, for corporates doing deals in the United Kingdom, this includes Transfer of Undertakings (Protection of Employment) legislation governing automatic transfers of employees in many corporate transactions.

    It seems highly unlikely that there will be any substantial downgrade of UK employment protection for employees. The political consequences of doing so are all too obvious and, in any event, it seems inevitable that any trade agreement negotiated with the European Union would require adherence to the vast majority of EU employment and social protections.

    Nevertheless, there may remain some scope in the longer term for the UK Government to gradually modify UK employment laws to make them more palatable to UK businesses and outside investment.

    The liability of internationally mobile employees for social security contributions is governed by a European directive that would presumably cease to apply if the United Kingdom leaves the European Union. Unless suitable arrangements are put in place, such individuals could find themselves liable to double contributions.

    For many organisations operating in the United Kingdom, the most immediate concern from a human resource perspective is likely to be addressing the negative impact on staff morale caused by the wide-ranging uncertainty Brexit has created. An effective internal communications strategy will be required to address this.

    HOW WE CAN HELP | ACCESS OUR BREXIT RESOURCE PAGE
    McDermott’s Brexit Group draws from experience across our legal disciplines and offices throughout Europe, the United States and Asia. As the laws, policies, and practices of the United Kingdom and the European Union evolve to address this new economic and political reality, we are ideally located and experienced to help companies evaluate the consequences of Brexit and protect their commercial interests. We will continually provide updates on Brexit, answer questions, or advise on how best to prepare for the effects of Brexit going forward here.

    Authors

    David Birchall

    Consultant

    London – 22 Bishopsgate

    Carolyn B. Gleason

    Partner

    Washington, DC

    Sabine Naugès

    Partner

    Paris

    Dr. Boris Uphoff

    Partner

    Munich, Düsseldorf

    Eleanor West

    Partner

    London – 22 Bishopsgate

    More insights

  • OIG Issues Report on Provider-Based Facilities, Urges CMS to Make Changes

    OIG Issues Report on Provider-Based Facilities, Urges CMS to Make Changes

    ARTICLE / CLIENT ALERT

    OIG Issues Report on Provider-Based Facilities, Urges CMS to Make Changes

    June 27, 2016

    Read time: 6 min

    Key takeaways
    Overview

    On June 16, 2016, the US Department of Health and Human Services Office of Inspector General (OIG) posted a report examining the Centers for Medicare & Medicaid Services’ oversight of billing by provider-based facilities. The OIG concluded that CMS is unable to adequately monitor provider-based facilities and ensure appropriate payments. The OIG also reaffirmed its 1999 recommendation to eliminate the provider-based designation.

    In depth

    On June 16, 2016, the US Department of Health and Human Services Office of Inspector General (OIG) posted a report examining the Centers for Medicare & Medicaid Services’ (CMS’s) oversight of billing by provider-based facilities. The OIG concluded that although CMS is taking steps to improve its oversight of provider-based facilities, CMS is unable to adequately monitor provider-based facilities and ensure appropriate billing and payment.

    The OIG continues to recommend elimination of the provider-based designation or implementation of equal payment for physician services, regardless of the setting where the services are provided. Alternatively, the OIG recommends that CMS (1) implement systems to monitor all provider-based facility billing, (2) make provider-based attestations mandatory, (3) ensure that CMS regional offices and Medicare Administrative Contractors (MACs) appropriately apply provider-based requirements when reviewing attestations, and (4) take appropriate action against hospitals and their off-campus provider-based facilities that do not meet the provider-based requirements.

    Background

    Facilities owned by and integrated with a hospital are permitted to bill Medicare as a hospital outpatient department (i.e., a provider-based facility), which results in Medicare making separate payments for a facility fee and professional fee associated with each service furnished at the provider-based facility. This generally results in the total Medicare payment for services furnished at a provider-based facility being higher than the total Medicare payment for the same services furnished in a freestanding (i.e., non-provider-based) facility, where Medicare makes only a single payment for the service.

    To qualify as provider-based, a facility—which may be on-campus (within 250 yards of the main provider) or off-campus (greater than 250 yards from the main provider)—must meet certain requirements, outlined at 42 CFR § 413.65. Hospitals may voluntarily submit a provider-based attestation (PBA) to CMS documenting that a facility meets the requirements to bill as a provider-based facility. Approval of a PBA by CMS provides certain protection to the hospital in the event that CMS later determines that the facility did not meet the requirements to bill as a provider-based facility.

    In 1999, the OIG recommended eliminating the provider-based designation because oversight challenges and increased costs to Medicare and its beneficiaries were not balanced out by any documented benefit of having the provider-based designation. The Medicare Payment Advisory Commission (MedPAC) has also recommended equal payments for certain services provided in hospital outpatient departments and physician offices, rather than increased reimbursement for services at provider-based facilities. Consistent with these recommendations, the Bipartisan Budget Act of 2015 mandates that effective January 1, 2017, Medicare payments for most items and services furnished at new (as of November 2, 2015) off-campus provider-based facilities will be made under the applicable non-hospital payment system.

    The OIG Report

    The OIG surveyed 333 hospitals regarding their ownership of provider-based facilities; assessed documentation of 50 hospitals that reported owning off-campus provider-based facilities but had not submitted the voluntary PBA to determine whether the facilities met the provider-based requirements; assessed the extent to which CMS has methods to oversee provider-based billing; and analyzed challenges with CMS’s review process of PBAs.

    The OIG found the following:

    • Half of the 333 hospitals surveyed owned at least one provider-based facility.
    • More than 75 percent of the 50 hospitals that had not submitted a PBA owned off-campus facilities that did not meet at least one of the provider-based requirements.
    • CMS cannot determine the amount of overpayments for on-campus provider-based facilities or multiple off-campus facilities owned by the same hospital in one building or campus if the physician claim does not specify the exact location of the service.
    • CMS has difficulty obtaining the hospital documentation necessary to review PBAs.

    OIG Recommendations and CMS Response

    The OIG reaffirmed its recommendation to eliminate the provider-based designation or implement MedPAC’s recommendation to equalize payment for the same physician services provided in different settings. If CMS does not eliminate or equalize provider-based payments, however, the OIG provided four recommendations.

    Monitoring of Provider-Based Facilities’ Billing

    First, the OIG recommended that CMS implement systems to monitor all provider-based facilities’ billing. CMS partially concurred with the recommendation, stating that the primary concerns are for off-campus provider-based facilities, rather than on-campus provider-based facilities, so CMS does not view it as efficient to allocate resources distinguishing among services that are provided in on-campus provider-based facilities and those provided on the main campus of the hospital.

    Mandatory Provider-Based Attestations

    Second, the OIG recommended that CMS make PBAs mandatory for all provider-based facilities. Although CMS said it shares the OIG’s concerns that there are vulnerabilities in provider-based billing, CMS disagreed with this recommendation and instead has taken steps to remedy the problem, including implementing a new modifier and place-of-service codes for claims furnished in off-campus provider-based facilities. Further, CMS stated that the “amendments made by section 603 of the Bipartisan Budget Act of 2015 also require certain off-campus provider-based entities to be paid under applicable payment systems other than the OPPS rate . . . which may limit the vulnerability identified by the OIG in provider-based billing.” CMS noted, however, that it will consider whether “additional activities” are needed to further address issues with overpayments to off-campus facilities.

    Better Review of Provider-Based Attestations

    Third, the OIG recommended—and CMS concurred—that CMS regional offices and MACs appropriately apply provider-based requirements when reviewing PBAs.

    Overpayment Recovery

    Fourth, the OIG recommended that CMS take appropriate action against hospitals and their off-campus provider-based facilities that do not meet the provider-based requirements. CMS concurred and stated that it will work with the MACs to recover overpayments.

    Conclusion

    The OIG’s report is consistent with historic OIG and MedPAC concerns about provider-based facilities. Coupled with the amendments made by § 603 of the Bipartisan Budget Act of 2015 and CMS’s response to this OIG report, all provider-based locations, both on- and off-campus, will likely continue to face increasing scrutiny. Hospitals should ensure that any facilities currently being treated as provider-based meet all requirements for provider-based status, and should evaluate whether to submit PBAs for provider-based facilities.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Monica Wallace

    Partner

    Chicago

    More insights

  • More Paid Sick Leave: The New Trend Sweeping California

    ARTICLE

    More Paid Sick Leave: The New Trend Sweeping California

    June 27, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Chris Scheithauer and Michael Graham wrote this bylined article about mandated sick leave for employees in California. A new state law says the total cap on sick leave accrual cannot be less than six days (48 hours), but the authors wrote that various cities in the state “have gone further and require employers to offer even more paid sick leave than that required statewide. Employers with employees throughout California must be wary of this patchwork of laws and ordinances.”
    Read the full article.

    In depth
    Authors
    More insights

  • Managing the Transition to Transformation: Is Your Organization Ready for the Shift to Alternative and Quality-Based Payment Models?

    Managing the Transition to Transformation: Is Your Organization Ready for the Shift to Alternative and Quality-Based Payment Models?

    ARTICLE / MANAGING THE TRANSITION TO TRANSFORMATION

    Managing the Transition to Transformation: Is Your Organization Ready for the Shift to Alternative and Quality-Based Payment Models?

    June 23, 2016

    Read time: 6 min

    Key takeaways
    Overview

    McDermott’s Managing the Transition to Transformation series is designed to help health systems and other health care industry leaders address the many challenges presented by the transformation in payment and care delivery models. The goal of this series is to help organizations prepare so that they are not only competitive, but can also thrive under alternative payment models (APMs) and quality-based reimbursement models (QBRs). This article discusses ways in which your organization can ready itself for this shift.

    In depth

    For many decades, at least since the passage of the Health Maintenance Organization Act of 1973, there have been reform efforts focused on moving the United States health care system away from fee-for-service (FFS) reimbursement and toward models designed to reward quality, value and outcomes (often grouped together under the umbrella of cost-effectiveness). We are in the midst of such an effort now, with a variety of alternative payment models (APMs) and quality-based reimbursement models (QBRs) in place or being implemented. Providers must be prepared to embrace these changes if they are to thrive. McDermott’s Managing the Transition to Transformation series is designed to help health systems and other health care industry leaders address the many challenges presented by the transformation in payment and care delivery models.

    APMs and QBRs tie financial success to improving quality and controlling costs, and weaken the relationship between volume and financial success. As a consequence, the new payment models can completely change the value proposition in a health care enterprise and transform fundamental approaches to the delivery of health care services. For example, in a population health management model, higher volumes can be financially damaging instead of accretive. The collateral consequences of these types of shifts are not difficult to imagine, as relationships among providers change to address the new incentives. Fundamental system structures, compliance efforts and board oversight functions all may be affected. Further, the shifting incentives result in new ways to think about fraud and abuse, antitrust and tax exemption laws.

    This transition is not easy, however. APMs and QBRs are not one-size-fits-all propositions. Rather, they represent a variety of approaches, each with its own set of requirements and incentives (see chart below). Adding to the difficulties and challenges health care providers face is the reality that during the transition they must operate in both worlds, with contracts that present fundamentally inconsistent financial incentives. Understanding the impossibility of designing a system that can excel in both environments, health care providers will have to decide where their “tipping point” is and at what point they align organizationally and strategically to the new payment world.

    Given the long history of similar efforts that have failed, some skepticism about whether the system really will transform to APMs and QBRs is understandable. There are, however, many reasons to believe that the current trend is real and that the changes, this time, will be systemic and transformational. Among the reasons to think this is not déjà vu are: (a) the nature of APMs and QBRs is not overly prescriptive, which is causing health care providers to experiment to find what works within an overall framework of lower costs and improving quality; (b) a revolution in health information technology has resulted in providers who have much more robust, real-time data to inform care management initiatives; (c) the pressure to control costs has only intensified; (d) consolidation in the provider market has created vertically integrated health systems that have the infrastructure to embrace and succeed under APMs and QBRs; and (e) APM and QBR initiatives in the recent past, albeit limited, have created a meaningful base of knowledge, on the part of providers and private and public payers, upon which to build. But perhaps the most compelling reason to think the transition will be transformative is the fact that the federal government, and in particular the Medicare program, is taking the lead.

    The Department of Health and Human Services has set a goal of tying 30 percent of FFS Medicare payments to quality or value by the end of 2016, with that growing to 50 percent by 2018 (see chart below). The Medicare program has never set such goals before. In repealing the sustainable growth rate approach, the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) established the Merit-Based Incentive Payment System (MIPS). Starting in 2019, MIPS will include substantial financial incentives for physicians and certain other eligible professionals to participate in APMs. On the hospital side, the Comprehensive Care for Joint Replacement requires certain hospitals to participate in retrospective bundling of acute care, post-acute care and physician services for Medicare beneficiaries receiving certain joint replacements. As a mandatory program for designated hospitals, this represents a fundamental shift in how Medicare pays for these services. This is just a small sample of a broad range of reimbursement changes being spearheaded by the Center for Medicare & Medicaid Services.

    The transition from FFS to the transformative under APMs and QBRs will pose a series of questions and challenges for health care systems and other industry leaders, the primary question being: How can I prepare my organization so that it is not only competitive, but thrives under APMs and QBRs? The goal of McDermott’s Managing the Transition to Transformation series is to help answer this question.

    What you can expect from the Managing the Transition to Transformation series?

    • Focused, succinct and practical articles covering the range of issues and questions that will arise from the transformation to APMs and QBRs.
    • Identification of indirect issues and considerations frequently overlooked when considering payment reform models.
    • A resource that general counsels can use to help internal clients anticipate and address emerging issues before they arise.

    Topics of individual articles will include:

    • MACRA and the Government’s Role in the Transformation
    • Strategies for Thriving in an Alternative Payment World
    • Fraud and Abuse in the Age of Payment Reform
    • Implications for Governance
    • Provider-Payor Integration
    • Quality and Payment Reform
    • Digital Health
    • Antitrust and Integrating Integrated Systems

     

    Authors

    Charles R. Buck

    Partner

    Boston

    Gary Scott Davis PA

    Senior Counsel

    Miami

    More insights

  • Claim Against a Shareholder-Guarantor

    ARTICLE

    Claim Against a Shareholder-Guarantor

    June 2016

    Read time: 2 min

    Key takeaways
    Overview

    Thiemo Schäfer wrote this bylined article on the December 2015 Order of the Higher Regional Court of Duesseldorf, upholding a claim against a shareholder-guarantor under Section 143 III of the Insolvency Code despite the creditor’s waiver of its rights under the guarantee.

    In depth
    Authors
    More insights

  • Second Circuit Defines Adequate Capitalization in Fraudulent Transfer Case

    Second Circuit Defines Adequate Capitalization in Fraudulent Transfer Case

    ARTICLE / CLIENT ALERT

    Second Circuit Defines Adequate Capitalization in Fraudulent Transfer Case

    June 21, 2016

    Read time: 7 min

    Key takeaways
    Overview

    A debtor’s pre-bankruptcy repurchase of its stock for $150 million was not a fraudulent transfer because the debtor “could have sold off enough of its assets or alternatively obtained sufficient credit to continue its business for the foreseeable future,” held the U.S. Court of Appeals for the Second Circuit on June 15, 2016. In re Adelphia Communications Corp., 2016 WL3315847, *2 (2d Cir. June 15, 2016). Affirming the lower courts, the Second Circuit stressed that “the issue of adequate capitalization,” the “sole issue presented on appeal … came down to a battle of experts,” with the “defendants’ experts” being “more persuasive.” Id. at *2.

    Relevance

    The creditors’ “Recovery Trust” in Adelphia challenged the debtor’s stock repurchase, made three years prior to bankruptcy, under the applicable Pennsylvania version of the Uniform Fraudulent Transfer Act (“UFTA”) because the transfer was made outside the relevant Bankruptcy Code reachback (Code § 546 (a)(1). As the Second Circuit noted, “Recovery Trust brought a claim under [Code] §544(b) which allows it to avoid any transfer under applicable state law … . ” Id. at *1. Further, “courts construe [UFTA] consistently with the provisions of the Bankruptcy Code that address constructive fraudulent transfers… .” For that reason, like the district court and the parties, it also relied “on decisions of other federal courts interpreting relevant provisions of the … Code.” Id.

    Insolvency was not an issue on appeal because the Recovery Trust in the district court accepted the bankruptcy court’s finding that the debtor “had an equity cushion of approximately $2.5 billion at the time of the challenged transaction.” 2015 U.S. Dist. LEXIS, at * 10. Under the relevant section of UFTA [§ 4(a)(2)(i)] “a [creditor or] trustee may avoid any transfer of an interest of the debtor if (1) the property is transferred for less than fair consideration and (2) either (a) the debtor was insolvent on the date of the transfer or (b) the debtor’s remaining assets were unreasonably small in relation to the transaction.” 2016 WL 3315847, at *1. Thus, because the debtor admittedly received no “reasonably equivalent value” in exchange for its cash payment, 512 B.R. at 494, the only question here was whether the debtor’s assets were “unreasonably small” at the time of the challenged transfer. Id.

    Analysis

    The court stressed the factual nature of its analysis. “Generally ‘adequacy of capital’ presents a mixed question of law and fact.” Id. at *1, citing Moody v. Sec. Pac. Bus. Credit, Inc., 971 F.2d 1056, 1063 (3d Cir. 1992). Accordingly, it reviewed the “district court’s relevant factual findings for clear error.” Id.

    Legal Standard

    Other courts, explained the Second Circuit, have interpreted the UFTA’s “unreasonably small” language “to describe a situation where a transaction leaves a debtor ‘technically solvent but doomed to fail.’” Id. at *2, citing MFS/Sun Life Tr. High-Yield Series v. Van Dusen Airport Srvs. Co., 910 F. Supp. 913, 944 (S.D.N.Y. 1995) (citing Moody, 971 F.2d at 1070 & n.22). Courts in this context focus “on reasonable foreseeability,” and look at whether “the debtor had such minimal assets that insolvency was inevitable in the reasonably foreseeable future” at the time of the transfer. Id.  

    Among the facts that courts look at are the debtors’ “debt to equity ratio, its historical capital cushion, and the need for working capital in the specific industry at issue.” Id., citing MFS/Sun Life Tr., 910 F. Supp. at 944. “Also relevant are ‘all reasonably anticipated relevant sources of operating funds, which may include new equity infusions, cash from operations, or cash from secured or unsecured loans over the relevant time period.’” Id., citing Moody, 971 F.2d at 1072 n. 24. See also In re Jackson, 459 F.3d 117, 123 (1st Cir. 2006) (under New Hampshire version of UFTA, courts consider debtor’s ability to “generate enough cash from operations and sales of assets to pay its debts and remain financially stable” after challenged transfer). Finally, “courts do not evaluate the financial condition of the debtor in isolation; they compare the subject company to peers in its industry.” 2016 WL 331584 at *2.

    Application to Facts

    The court rejected the Recovery Trust’s “argument that the district court improperly conflated its analysis of [the debtor’s] solvency with its evaluation of whether [it] had unreasonably small capital,” noting that the concepts are distinct, “but overlap.” Id., citing Moody, 971 F.2d at 1069-71. “The district court … analyzed [the debtor’s] solvency separately from the adequacy of its capital.” Id. Here, “at the time of the challenged transfer [the Debtor] needed approximately $600 million to meet its capital needs over the next 3 years and … [the challenged] transfer still left the company with an equity cushion of approximately $2.5 billion.” Id. Despite the debtor’s being overleveraged with a negative cash flow, being in default under existing bond indentures, and “beset by ongoing fraud within the company,” it “could have sold off enough of its assets or alternatively obtained sufficient credit to continue its business for the foreseeable future.” Id. In fact, the defendants’ experts showed with declarations and trial testimony “that similarly-situated companies in the [debtor’s] industry were able to access capital markets despite having negative cash flows and/or having high leverage ratios, and that numerous other companies obtained access to capital markets after disclosing a fraud.” Id.

    Comment

    The Adelphia decision is consistent with the few decisions handed down in this context by other Courts of Appeals. More importantly, it confirms that proving the debtor’s insolvency is unnecessary. In re Jackson, 459 F.3d at 124 (held, “[t]his requirement in fraudulent transfer law does not require a finding of post-transfer insolvency.”); Steph v. Branch, 255 F. Supp. 526 (E.D. Okla. 1966), aff’d, 389 F.2d 233 (10th Cir. 1968); Moody, 971 F.2d. at 1071-72 (3d Cir. 1992) (“unreasonably small capital denotes a financial condition short of equitable insolvency”). It is sufficient for the plaintiff trustee or creditors to show that the debtor was constantly behind in paying its bills or continued its business under serious financial risk. Jackson, 459 F.3d. at 123 (court should examine ability of debtor to generate enough cash from operations and sales of assets to pay its debts and remain financially stable); In re Desert View Bldg. Supplies Inc., 475 F. Supp. 693 (D. Nev. 1978), aff’d without opinion 633 F. dd 225 (9th Cir. 1980) (parent pledged subsidiary stock to bank as collateral for loan and then defaulted on payments; to refinance, parent caused subsidiary to borrow from bank, with loan proceeds to pay off parent’s initial loan; held loan left subsidiary with unreasonably small capital to operate in business; proof supplied by testimony of bank’s lending officer that subsidiary had extremely low cash on hand for a business of its size).

    Authored by Michael L. Cook.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or the author.


    This information has been prepared by Schulte Roth & Zabel LLP (“SRZ”) for general informational purposes only. It does not constitute legal advice, and is presented without any representation or warranty as to its accuracy, completeness or timeliness. Transmission or receipt of this information does not create an attorney-client relationship with SRZ. Electronic mail or other communications with SRZ cannot be guaranteed to be confidential and will not (without SRZ agreement) create an attorney-client relationship with SRZ. Parties seeking advice should consult with legal counsel familiar with their particular circumstances. The contents of these materials may constitute attorney advertising under the regulations of various jurisdictions.

    In depth
    Authors
    More insights

  • Brexit: Will the European Patent Unit Be Paralyzed Before It Comes Into Being?

    ARTICLE

    Brexit: Will the European Patent Unit Be Paralyzed Before It Comes Into Being?

    June 21, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Boris Uphoff and Laura Morelli wrote this bylined article on how a UK exit from the European Union (Brexit) could impact the European Patent Unit plan to confer uniform patent protection in all 26 EU Member States. “If the UK approves Brexit, the most likely scenario would be that the Patent Unit system has to be renegotiated. Even if this can be done, without the UK’s participation the Patent Unit would lose considerable value,” the authors wrote.

    Read the full article.

    In depth
    Authors

    Dr. Boris Uphoff

    Partner

    Munich, Düsseldorf

    More insights

  • SALT Implications of Proposed Section 385 Debt-Equity Regulations

    ARTICLE

    SALT Implications of Proposed Section 385 Debt-Equity Regulations

    June 20, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Peter Faber wrote this bylined article on the potential state and local tax issues created by proposed revisions to IRC Section 385 regulations. Taxpayers and tax lawyers alike “were taken by surprise” with the revisions, he continued, noting that although they were intended to address corporate inversions, “their application went well beyond inversions, and they apply to intercorporate debt regardless of whether it occurs in an international context.”

    In depth
    Authors
    More insights

  • Foreign Losses – A Journey through Time from 1966 to 2016

    Foreign Losses – A Journey through Time from 1966 to 2016

    ARTICLE

    Foreign Losses – A Journey through Time from 1966 to 2016

    2016

    Read time: 2 min

    Key takeaways
    Overview

    Dr. Dirk Pohl and Dr. Gero Burwitz authored this article, which considered the issue of foreign losses in light of the fiftieth anniversary of the book, “German Tax on Foreign Transactions” by Prof. Dr. Arndt Raupach.

    In depth
    Authors

    Dr. Dirk Pohl

    Partner

    Munich

    Dr. Gero Burwitz

    Partner

    Munich

    More insights